CD19 and lymphoma: Therapies with adoptive transfer of autologous T cells engineered ex vivo with a chimeric antigen receptor (CAR) directed against CD19 are efficacious and approved for refractory and relapse B-cell leukaemia and lymphoma, while B-cell maturation antigen-directed CAR T-cell treatment is approved for multiple myeloma1–4.